Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Week 2 adalimumab levels predict clinical remission in IBD patients
Serum levels of adalimumab at week 2 is associated with short-term clinical remission in patients with inflammatory bowel disease (IBD), a study has shown.
Week 2 adalimumab levels predict clinical remission in IBD patients
23 Sep 2022Rocatinlimab a new treatment option for head and neck AD?
Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.
Rocatinlimab a new treatment option for head and neck AD?
23 Sep 2022Evolocumab safety, efficacy affirmed in Arabic patients
PCSK9 inhibition with evolocumab produces clinically meaningful and sustained reductions in certain lipid parameters in a predominantly Arabic population of individuals with familial hypercholesterolaemia (FH) and other non-FH indications, according to a study.
Evolocumab safety, efficacy affirmed in Arabic patients
23 Sep 2022DANFLU-1: High-dose quadrivalent flu vax reduces hospitalization, death in older adults
Older adults who receive a high-dose quadrivalent influenza vaccine have a 49 percent reduced risk of death and a 64 percent reduced risk of hospitalization for influenza or pneumonia compared with those who receive a standard-dose vaccine, results of the DANFLU-1 study showed.
DANFLU-1: High-dose quadrivalent flu vax reduces hospitalization, death in older adults
22 Sep 2022POP: Delayed intake, missing one pill not a major reason for contraceptive failure
Delayed intake of a progestogen-only pill (POP) or missing one pill does not necessarily reduce its theoretical contraceptive protection, with little effect on cervical mucus and ovulation, as shown in a study.
POP: Delayed intake, missing one pill not a major reason for contraceptive failure
22 Sep 2022Inhaled IFN-β1a shows favourable signals for hospitalized COVID-19 patients
In the phase III SPRINTER trial, inhaled interferon-beta-1a (IFN-β1a) showed encouraging signals for preventing disease progression or death in hospitalized COVID-19 patients.
Inhaled IFN-β1a shows favourable signals for hospitalized COVID-19 patients
22 Sep 2022ALLEGRO-LT shows long-term benefit of ritlecitinib for alopecia areata
In the interim analysis of the ongoing phase III ALLEGRO-LT trial, the investigational oral JAK3*/TEC inhibitor ritlecitinib demonstrated long-term safety and remarkable scalp hair regrowth in adults and adolescents with alopecia areata (AA).